Floatz logo

Zanubrutinib

Colorectal Cancer Metastatic

Sun Yat-sen UniversitySmall moleculePhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

89 Active assets in the Colorectal Cancer Metastatic cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Ciusss de L'Est de l'Île de Montréal
Phase 4BB
Irinotecan
Oncolytics Biotech
Phase 4BB
Calcium folinate pentahydrate
Ciusss de L'Est de l'Île de Montréal
Phase 4BB
Aflibercept
Sanofi
Phase 3BB
Cetuximab
Charite University, Berlin, Germany
Phase 4BB

View all 50 →

Same molecule, other indications

Zanubrutinib is also rated in:

B-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
splenic marginal zone lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
marginal zone lymphomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →